Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Endocrinology

Cabergoline vs Bromocriptine for Prolactinoma Treatment

At a Glance

Both cabergoline and bromocriptine effectively treat prolactinomas by lowering prolactin and shrinking the tumor. Cabergoline is the preferred first-line treatment because it is more effective, requires dosing only 1-2 times a week, and generally causes fewer stomach side effects than bromocriptine.

In this answer

4 sections

01

Effectiveness and Timeline

02

Dosing and Convenience

03

Side Effects and Tolerability

04

Pregnancy and Fertility

When treating a prolactinoma, both cabergoline and bromocriptine work by mimicking the brain chemical dopamine to lower prolactin levels and shrink the tumor. However, cabergoline is considered the first-line (preferred) treatment for most patients [1]. It is generally more effective, has fewer side effects, and is taken only once or twice a week [2][3]. Bromocriptine is an older medication that must be taken daily, but it is still an effective alternative and is sometimes preferred for specific situations, such as planned pregnancy, or when medication cost is a primary concern [4][5].

Effectiveness and Timeline

Cabergoline is significantly more effective than bromocriptine at normalizing prolactin levels and reducing tumor size [2][6].

  • High Success Rates for Both Sexes: Patients taking cabergoline are more likely to achieve normal prolactin levels and experience relief from symptoms [7]. For women, this typically means restoring missed periods (amenorrhea) and stopping abnormal milk production (galactorrhea). For men, the medication is highly effective at restoring normal testosterone levels, resolving erectile dysfunction, and improving male fertility [7].
  • Timeline of Results: Once you start treatment, your prolactin levels often begin dropping rapidly, sometimes reaching normal levels within the first few weeks [8]. However, visible tumor shrinkage on an MRI is a slower process that typically takes several months of consistent use.
  • Overcoming Resistance: If a patient’s tumor does not respond well to bromocriptine (a condition called dopamine agonist resistance), switching to cabergoline is a standard and highly successful approach [9].
  • Duration of Treatment: Medication for a prolactinoma is often a long-term commitment, usually lasting a few years. However, if your prolactin levels remain normal and your tumor shrinks significantly, your doctor may eventually discuss a trial period of lowering your dose or stopping the medication.

Dosing and Convenience

A major difference between the two medications is how often you need to take them.

  • Cabergoline: Typically taken by mouth just once or twice a week because it remains active in the body for a long time [10][3].
  • Bromocriptine: Requires daily dosing, and sometimes multiple times a day, which can make it harder for patients to stick to their treatment schedule [3].

Side Effects and Tolerability

Side effects are common with both medications, particularly during the first few weeks of treatment, but their safety profiles and daily impacts differ.

  • Everyday Side Effects: While cabergoline is much better tolerated overall, you may still experience mild side effects like nausea, dizziness, fatigue, or mild headaches when you first start taking it [1][11]. Actionable Tip: Taking either medication at bedtime or with a meal can significantly help minimize nausea and dizziness.
  • Managing Bromocriptine Nausea: Bromocriptine frequently causes much more intense stomach upset than cabergoline [2][12]. To reduce severe nausea, doctors sometimes prescribe oral bromocriptine pills to be administered vaginally [13]. While this is technically an “off-label” use (meaning it differs from the package instructions), it is a widely accepted and safe workaround prescribed by specialists to bypass the stomach entirely.
  • Impulse Control Disorders: A rare but important side effect of all dopamine agonists is the potential to trigger impulse control disorders (ICDs) [14]. Patients may suddenly develop strong, uncontrollable urges such as compulsive gambling, compulsive shopping, binge eating, or hypersexuality [15]. It is strongly recommended to inform your doctor and family members about this risk so they can monitor for sudden behavioral changes, which usually resolve if the dose is lowered [14][15].
  • Heart Valve Risk with Cabergoline: Long-term use of cabergoline at very high cumulative doses carries a small risk of cardiac valvulopathy (thickening or leaking of the heart valves) [16][17]. While the low doses used for prolactinomas are generally considered safe, doctors may still recommend periodic echocardiograms (ultrasounds of the heart) to monitor your heart over time [18][19].

Pregnancy and Fertility

Both medications are highly effective at restoring fertility for both men and women with hyperprolactinemia [20]. However, their roles during pregnancy differ slightly.

  • Stopping Medication: For most patients, doctors recommend stopping either dopamine agonist as soon as a pregnancy is confirmed [21]. The exception is for patients with large, invasive tumors (macroprolactinomas), who may need to continue taking their medication to prevent the tumor from growing during pregnancy [22].
  • Bromocriptine’s Track Record: Bromocriptine has been around longer and has the largest amount of historical safety data regarding pregnancy. For this reason, it has traditionally been the favorite for women actively trying to conceive [23][5].
  • Cabergoline and Pregnancy: Current evidence shows cabergoline is also safe during early pregnancy, and does not increase the risk of miscarriages or birth defects [20][24]. Because bromocriptine is often poorly tolerated, many specialists now comfortably prescribe cabergoline for patients trying to conceive [5].

Common questions in this guide

Which is better for treating a prolactinoma: cabergoline or bromocriptine?
Cabergoline is generally considered the preferred first-line treatment for most patients. It is typically more effective at normalizing prolactin levels, causes fewer side effects, and is more convenient since it only needs to be taken once or twice a week.
How quickly do prolactinoma medications work?
Prolactin levels often begin to drop rapidly, sometimes reaching normal ranges within the first few weeks of starting treatment. However, visibly shrinking the tumor on an MRI is a slower process that takes several months of consistent medication use.
Can I take cabergoline or bromocriptine if I am trying to get pregnant?
Yes, both medications are highly effective at restoring fertility in men and women. While bromocriptine has a longer history of use in pregnancy, current evidence shows cabergoline is also safe during early pregnancy and is increasingly prescribed for patients trying to conceive.
What are the most common side effects of prolactinoma medications?
During the first few weeks, you may experience nausea, dizziness, fatigue, or mild headaches. Bromocriptine often causes more intense stomach upset than cabergoline. Taking either medication at bedtime or with a meal can help reduce these everyday side effects.
What are impulse control disorders and why do they happen with these medications?
A rare side effect of dopamine agonist medications is the sudden development of strong, uncontrollable urges, such as compulsive gambling, shopping, or eating. If you or your family notice these behavioral changes, tell your doctor, as they usually resolve when the dose is lowered.
Why might my doctor recommend an echocardiogram if I take cabergoline?
Long-term use of cabergoline at very high cumulative doses carries a small risk of heart valve thickening or leaking. Even though the low doses used for prolactinomas are generally safe, periodic ultrasounds of the heart help monitor for any potential changes over time.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific tumor size, hormone levels, and insurance coverage, which medication do you recommend and why?
  2. 2.What should I do if I experience severe nausea or dizziness when I first start taking my medication?
  3. 3.Are there any baseline tests, like an echocardiogram or specific blood panels, that I need before starting cabergoline?
  4. 4.How frequently will we monitor my prolactin levels to see if the medication is working, and when should we expect to see results?
  5. 5.What is the long-term plan? Will I need to take this medication indefinitely, or can we eventually try reducing the dose?
  6. 6.Who should my family and I contact if we notice sudden behavioral changes or compulsive urges?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Cabergoline Cause a CSF Leak? | Inciteful MedDoes Cabergoline Cause Impulse Control Disorders?Why Does a Giant Prolactinoma Show Normal Blood Tests?Is Prolactinoma Genetic? MEN1, AIP & Hereditary RiskMacroprolactin: Is My High Prolactin A False Positive?Is High Prolactin Caused by Medication or a Prolactinoma?What Are the Emergency Signs of Pituitary Apoplexy?Can I Get Pregnant With a Prolactinoma? Is Medication Safe?Does a Prolactinoma Cause Bone Loss and Osteoporosis?Why Are Prolactinomas Diagnosed Later in Men?What is the Recovery Time for Prolactinoma Surgery?Can a Large Prolactinoma Affect Your Other Hormones?When Can I Stop Taking Cabergoline for Prolactinoma?Why Do I Need an Echocardiogram on Cabergoline?

References

References (24)
  1. 1

    A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

    Mishra R, Konar SK, Shrivastava A, et al.

    Indian journal of endocrinology and metabolism 2021; (25(6)):493-506 doi:10.4103/ijem.ijem_338_21.

    PMID: 35355923
  2. 2

    Cabergoline or bromocriptine for prolactinoma?

    Triantafilo N, Castro-Gutiérrez V, Rada G

    Medwave 2016; (16(Suppl3)):e6545 doi:10.5867/medwave.2016.6545.

    PMID: 27689434
  3. 3

    Clinical and Laboratory Characteristics of Hyperprolactinemia in Children and Adolescents: National Survey

    Eren E, Törel Ergür A, İşgüven ŞP, et al.

    Journal of clinical research in pediatric endocrinology 2019; (11(2)):149-156 doi:10.4274/jcrpe.galenos.2018.2018.0206.

    PMID: 30396878
  4. 4

    Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.

    Oshige T, Nakamura Y, Sasaki Y, et al.

    Internal medicine (Tokyo, Japan) 2019; (58(21)):3125-3128 doi:10.2169/internalmedicine.2755-19.

    PMID: 31243214
  5. 5

    Cabergoline Use and Pregnancy Outcomes: A Systematic Review.

    Otis AS, Brochet MS, Tremblay Z, et al.

    Birth defects research 2025; (117(3)):e2464 doi:10.1002/bdr2.2464.

    PMID: 40116053
  6. 6

    The Role of Dopamine Agonists in Pituitary Adenomas.

    Giraldi EA, Ioachimescu AG

    Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

    PMID: 32741482
  7. 7

    Sexual Functioning in Hyperprolactinemic Patients Treated With Cabergoline or Bromocriptine.

    Krysiak R, Okopień B

    American journal of therapeutics 2019; (26(4)):e433-e440 doi:10.1097/MJT.0000000000000777.

    PMID: 29746287
  8. 8

    Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study.

    Rudman Y, Simon N, Shimon R, et al.

    Endocrine 2025; (89(1)):212-221 doi:10.1007/s12020-025-04215-w.

    PMID: 40199840
  9. 9

    Ectopic Cavernous Sinus Microprolactinoma Treated Medically.

    Minns RM, Barranco-Trabi J, Yiu AC, et al.

    Military medicine 2023; (188(5-6)):1304-1306 doi:10.1093/milmed/usac182.

    PMID: 35758408
  10. 10

    Alternative Treatment Strategies in Women Poorly Tolerating Moderate Doses of Bromocriptine.

    Krysiak R, Szkróbka W, Okopień B

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017; (125(6)):360-364 doi:10.1055/s-0042-123041.

    PMID: 28073129
  11. 11

    Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas.

    Rudman Y, Shimon I

    Best practice & research. Clinical endocrinology & metabolism 2026; 102095 doi:10.1016/j.beem.2026.102095.

    PMID: 41724640
  12. 12

    Antipsychotic Induced Symptomatic Hyperprolactinemia: Are Dopamine Agonists Safe?

    Lertxundi U, Domingo-Echaburu S, Peral J, García M

    Psychopharmacology bulletin 2011; (44(3)):66-68 doi:10.64719/pb.4078.

    PMID: 27738363
  13. 13

    Real-world value of cabergoline in the treatment of acromegaly.

    Shimon I

    Best practice & research. Clinical endocrinology & metabolism 2024; (38(4)):101887 doi:10.1016/j.beem.2024.101887.

    PMID: 38443225
  14. 14

    Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.

    Celik E, Ozkaya HM, Poyraz BC, et al.

    Endocrine 2018; (62(3)):692-700 doi:10.1007/s12020-018-1744-8.

    PMID: 30206771
  15. 15

    Cabergoline and impulse control disorders: Screening patients with pituitary adenomas in an endocrinology clinic.

    Lydiatt M, Grissom B, Givens J, et al.

    Journal of psychiatric research 2026; (195()):105-112 doi:10.1016/j.jpsychires.2026.01.041.

    PMID: 41619686
  16. 16

    Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.

    Budayr A, Tan TC, Lo JC, et al.

    BMC endocrine disorders 2020; (20(1)):25 doi:10.1186/s12902-020-0507-8.

    PMID: 32075620
  17. 17

    Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.

    Khare S, Lila AR, Patil R, et al.

    Indian journal of endocrinology and metabolism 2017; (21(1)):154-159 doi:10.4103/2230-8210.196010.

    PMID: 28217516
  18. 18

    Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review.

    Gamble D, Fairley R, Harvey R, et al.

    Therapeutic advances in drug safety 2017; (8(7)):215-229 doi:10.1177/2042098617703647.

    PMID: 28845230
  19. 19

    Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints.

    Stiles CE, Lloyd G, Bhattacharyya S, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(2)):e711-e720 doi:10.1210/clinem/dgaa882.

    PMID: 33247916
  20. 20

    Prolactinoma and pregnancy: From the wish of conception to lactation.

    Maiter D

    Annales d'endocrinologie 2016; (77(2)):128-34.

    PMID: 27130071
  21. 21

    Prolactinomas in pregnancy: considerations before conception and during pregnancy.

    Glezer A, Bronstein MD

    Pituitary 2020; (23(1)):65-69 doi:10.1007/s11102-019-01010-5.

    PMID: 31792668
  22. 22

    Outcomes of Patients with Macroprolactinoma Desiring Pregnancy: Follow-Up to 23 Years from a Single Center.

    Tanrikulu S, Yarman S

    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2021; (53(6)):371-376 doi:10.1055/a-1468-4608.

    PMID: 33902136
  23. 23

    Pregnancy and Tumor Outcomes in Women with Prolactinoma.

    Araujo B, Belo S, Carvalho D

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2017; (125(10)):642-648 doi:10.1055/s-0043-112861.

    PMID: 28704852
  24. 24

    Managing Prolactinomas during Pregnancy.

    Almalki MH, Alzahrani S, Alshahrani F, et al.

    Frontiers in endocrinology 2015; (6()):85 doi:10.3389/fendo.2015.00085.

    PMID: 26074878

This information comparing prolactinoma medications is for educational purposes only and does not replace professional medical advice. Always consult your endocrinologist regarding your specific treatment plan and medication management.

Get notified when new evidence is published on Prolactinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.